



9-1-2020

## Prevalence of bacteriuria, candiduria and antibiotics susceptibility patterns among diabetic verses nondiabetic patients

Gamal El--Sherbiny

*Botany and Microbiology Department, Faculty of Science (Boys), Al-Azhar University Cairo, Egypt,*  
gamalelsherbiny1970@yahoo.com

Abdallah Elsaheed

*Botany and Microbiology Department, Faculty of Science (Boys), Al-Azhar University Cairo, Egypt.,*  
bedoelsaheed2010@gmail.com

Ahamed Radwan

*Botany and Microbiology Department, Faculty Science, Al-Azhar University, Cairo, Egypt,*  
ahamedradwan56@yahoo.com

Mostafa Mohamed

*Clinical Pathology Department, Faculty Medicine Helwan University Cairo ,Egypt,*  
mostafa.kamal@med.med.helwan.edu.eg

Follow this and additional works at: <https://aimj.researchcommons.org/journal>



Part of the [Medical Sciences Commons](#), [Obstetrics and Gynecology Commons](#), and the [Surgery Commons](#)

### How to Cite This Article

El--Sherbiny, Gamal; Elsaheed, Abdallah; Radwan, Ahamed; and Mohamed, Mostafa (2020) "Prevalence of bacteriuria, candiduria and antibiotics susceptibility patterns among diabetic verses nondiabetic patients," *Al-Azhar International Medical Journal*: Vol. 1: Iss. 9, Article 3.

DOI: <https://doi.org/10.21608/aimj.2020.38649.1297>

This Original Article is brought to you for free and open access by Al-Azhar International Medical Journal. It has been accepted for inclusion in Al-Azhar International Medical Journal by an authorized editor of Al-Azhar International Medical Journal. For more information, please contact [dryasserhelmy@gmail.com](mailto:dryasserhelmy@gmail.com).

## Prevalence of Bacteriuria, Candiduria, and Antibiotics Susceptibility Patterns Among Diabetic Versus Non-Diabetic Patients

Abdallah M. Elsaed<sup>1</sup> MSc.; Gamal M. El-Sherbiny<sup>1,\*</sup> PhD.; Ahamed A. A. Radwan<sup>1</sup> PhD.; Mostafa K. Mohammed<sup>2</sup> PhD.

### \* Corresponding Author:

Gamal M. El-Sherbiny

[gamalelsherbiny1970@azhar.edu.eg](mailto:gamalelsherbiny1970@azhar.edu.eg)

Received for publication April 26, 2020; Accepted August 25, 2020; Published online August 25, 2020.

**Copyright** 2020 The Authors published by Al-Azhar University, Faculty of Medicine, Cairo, Egypt. All rights reserved. This an open-access article distributed under the legal terms, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

doi: 10.21608/aimj.2020.38649.1297

<sup>1</sup>Botany and Microbiology Department, Faculty of Science (Boys), Al-Azhar University.

<sup>2</sup>Clinical Pathology Department, Faculty Medicine, Helwan University, Cairo, Egypt.

### ABSTRACT

**Aim of the work:** Assessment of the microbial species from diabetic and nondiabetic illness and their antibiotics susceptibility patterns.

**Materials and Methods:** Two hundred urine specimens were collected from illness in a duration period extending from July 2018 to July 2019 at Badr University Hospital-Helwan, Cairo, Egypt. Samples were collected on MacConkey, blood agar, and Sabouraud dextrose media. The microbial isolates were identified by microbiological methods. The antibiotic sensitivity was evaluated by the VITEK 2 compact automatic system and disk diffusion method.

**Results:** Only 120 samples exhibit growth with a prevalence rate of 60%, from total samples collected. The results revealed UTIs were found to be significantly higher in diabetic illness (79%) compared to nondiabetic illness (41%). One hundred and twenty microbial species were recovered from collected urine specimens (79 from diabetic and 41 nondiabetics). Pathogenic bacteria & Candida were represented with 96 isolates (80.0 %) and 24 isolates (20.0), respectively. Among the 96 bacterial isolates, *Escherichia coli* constituted, *Escherichia coli* (72.80%), *Klebsiella pneumonia* (22.88%), and *Staphylococcus aureus* (4.16%). Meropenem, imipenem, trimethoprim/ sulphamethoxazole, and norfloxacin highly effective antibiotics against *E. coli* and *Klebsiella pneumonia* while amoxicillin, erythromycin, and vancomycin low effective.

**Conclusion:** Diabetes disease a remarkable factor that stimulates UTIs. Higher frequency resistance to antibiotics in this study renders its indecency for empirical treatment and development of new empirical treatment.

**Keywords:** UTIS; diabetics; nondiabetics; antibiotics; resistance.

**Disclosure:** The authors have no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the authors.

**Authorship:** All authors have a substantial contribution to the article.

### INTRODUCTION

Urinary tract infections (UTIs) have long been recognized as a significant problem in nondiabetic patients and more dangerous in diabetic illness. In the world, three hundred and seventy-one million people have diabetes and it is estimated that by 2030 reach five hundred and fifty-two million.<sup>1,2</sup>

Diabetes is one of the top ten chronic diseases that cause death in the world.<sup>3</sup> Even though both males and females are susceptible to UTIs, but the females high susceptible to UTIs compared with males. More than 50% of females will develop UTIs in their lifetime and one from three females requires antibiotics due to UTIs.<sup>4,5</sup>

*Escherichia coli* are predominating bacteria causing UTIs. Classification of *Escherichia coli* was found belong to the family Enterobacteriaceae and represented 75 to 90% of UTIs.<sup>6</sup> Major studies

worldwide revealed that *Escherichia coli* is responsible for most UTIs.<sup>7</sup> *Escherichia coli* responsible for UTI in females and males is 58.2% and 31.4%, respectively.<sup>8</sup>

UTIs are initiated with *Escherichia coli*, which is a sitting in the gastrointestinal tract.<sup>6</sup> Commensal *Escherichia coli* acts as a storage of resistant genes and ability transferred to another pathogen bacteria.<sup>9</sup> Guidelines of the (IDSA) the advice antibiotics for the treatment of UTIs is sulphamethoxazole/ trimethoprim where the resistance spread is <10-20% recommend drug is ciprofloxacin.<sup>10</sup>

Aimed of the present study to assessment spread UTIs among nondiabetic and diabetic illness, a characterization the most spread microbes causing for it, and their antibiotics susceptibility patterns.

## MATERIALS AND METHODS

Two hundred urine specimens were collected from diabetic and nondiabetic patients in a duration period extending from July 2018 to July 2019 at Badr University Hospital-Helwan, Cairo, Egypt. The collected specimens were processed by microbiological methods and were cultivated on MacConkey agar, blood agar, and Sabouraud dextrose media. All media were readily obtained from (Oxoid, England).

### Assessment and Purification of Microbial Isolates

The plates containing MacConkey agar, blood agar, and Sabouraud dextrose media were inoculated with the collected clinical urine samples and were incubated at 35°C for 24 and 48h. The grown colonies were selected, picked up, purified, and then transferred to agar slants containing the same medium. The purified microbial isolates were subjected to a scheme of experimental identification.

### Identification of Microbial Isolates.

The pure cultures were characterized based on morphology, physiology, and biochemical tests using Microbiological Methods 8<sup>th</sup> Bergey's Manual of Systematic Bacteriology<sup>11,16</sup>. Characterization was confirmed by VITEK 2 compact automated system (Biomerieux Inc., Marcy l'Etoile, France). *Candida* isolates were identified using chromogenic agar media.<sup>12</sup>

### Antibiotic sensitivity Testing

Susceptibility of bacterial isolates to antibiotics was accompanied with a VITEK 2 compact automated system (Biomerieux Inc., Marcy l'Etoile, France) and disk diffusion method according to (CLSI) recommendation in 2015.<sup>13,16</sup>

## RESULTS

In this study, the cultivation of collected urine specimens on MacConkey agar, blood agar, and Sabouraud dextrose agar media revealed that UTIs were significantly higher infected with a ratio of 60% from total samples collected from diabetic and non-diabetic (Figure 1).


The specimens were collected from diabetic illness showed a highly infected with percentage (79%) compare with nondiabetic (41%). Female urine samples high infected rates in diabetic and nondiabetic patients compare with male samples (Figure 2).

One hundred and twenty microbial species recovered from positive urine specimens from diabetic and nondiabetic illness were included in the study. Pathogenic bacteria & *Candida* were represented by 96 isolates (80.0 %) and 24 isolates (20.0), respectively. Among the 96 bacterial isolates, *Escherichia coli* constituted (72.80%), *Klebsiella pneumonia* (22.88%), and *Staphylococcus aureus* (4.16%) (Figure 3).


Out of the 96 bacterial isolates, 63 (52.47) isolates were recovered from diabetic and 32 (26.65) bacterial species were isolated from nondiabetic patients. Out 24, *Candida* species; 23(19.15) isolates

were recovered from diabetic patients and 1 (.833) isolates were recovered from nondiabetic. The results were obtained from samples collected revealed that nondiabetic male and female infected with Gram-negative bacteria and candida, while diabetic samples infected with both Gram-(negative and positive) bacteria, and candida (Figure 4).

The antibiotic sensitivity patterns of Gram-negative bacterial species recovered from diabetic and nondiabetic illness showed that highly resistant to amoxicillin, erythromycin, and vancomycin. *Klebsiella pneumonia* isolates were found highly resistant to ceftazidime, cephadrine, cefadroxil, cephalexin, ampicillin/sulbactam, and trimethoprim/sulphamethoxazole than *Escherichia coli* isolates. Gram-positive bacteria *Staphylococcus aureus* was found to be resistant to amoxicillin but highly sensitive to amikacin, ciprofloxacin, gentamycin imipenem levofloxacin, meropenem, and norfloxacin. The highly effective antibiotics against *E. coli* and *Klebsiella pneumonia* were recovered from diabetic and nondiabetic illness were found to be meropenem, imipenem, trimethoprim/sulphamethoxazole, and norfloxacin (Figure 5,6,7,8 and 9).



**Fig. 1:** Prevalence infection rate of urine specimens collected from diabetic and nondiabetic illness.



**Fig. 2:** Prevalence of infected urine samples from diabetic and non-diabetic patient's male and female




Fig. 3: Prevalence of bacterial species rate in infected samples.




Fig. 4: Prevalence rate of bacterial species and candida in infected urine samples from diabetic and nondiabetic patients.




Fig. 5: Antibiotics profile of E. coli recovered from urine specimens diabetic illness male and female.







Fig. 6: Antibiotics profile of E. coli recovered from urine specimens nondiabetic illness male and female.



**Fig. 7:** Antibiotics profile of *Klebsiella pneumoniae* isolated from urine samples diabetic patient’s male and female



**Fig. 8:** Antibiotics profile of *Klebsiella pneumoniae* isolated from urine samples nondiabetic patient’s male and female



**Fig. 9:** Antibiotics profile of *S. aureus* recovered from urine specimens diabetic illness male and female

## DISCUSSION

SMILE & FS-LASIK were extremely effective, safe. In our study, the widespread presence of UTIs in non-diabetic and diabetic illnesses was 60% with a prevalence of 48% high remarkable bacteriuria and 12% candiduria. The spread rate from non-diabetic 32% bacteriuria and 1% candiduria whereas illness 64% bacteriuria and 23% candiduria. However, this finding difference with the results recorded from India (32%)<sup>17</sup> and similar results from Iraq (49.1%)<sup>18</sup> and Pakistan (51%).<sup>19</sup> The causing for this variance in the average of bacterial UTIs etiologies may be dissimilarity in, the ecology, community-habits, the quality of individual hygiene, or methodology used. *Candida* sp. is a general displaying factor of UTIs in diabetic illness.<sup>20,21</sup>

In this study, remarkable candiduria was found to be 23% in diabetic and 1% in nondiabetic. This findings difference with results recorded in Ethiopia (8.3%)<sup>20</sup>, and King Saudi Arabia (12%).<sup>22</sup>

In this study, *Escherichia coli* is the most common bacterial species and its pervasiveness was 58.29% with a discrepancy 33.31% from diabetic and 24.98% non-diabetic, similar to this study, *Escherichia coli* was also the most predominate bacteria with a ratio (69%).<sup>23</sup> Al-Asoufi et al., 2017 reported that *E. coli* is causing UTIs with a prevalence rate (44.8%) in diabetic and non-diabetic illnesses.<sup>24</sup>

The second frequently isolated bacteria were found to be *Klebsiella pneumonia* constituted (18.32%) from total microbial isolate, (10%) from diabetic and (8.32%) from nondiabetic illness. Karmaker et al., 2016 reported that *Klebsiella pneumonia* is responsible for UTIs with a prevalence rate (8%) in diabetic patients.<sup>25</sup> In the present study, *Staphylococcus aureus* is responsible for UTIs with a prevalence rate (4%) in diabetic patients, not present in nondiabetic patients. Kumar et al. (2019) reported that coagulase-positive *Staphylococcus* from urine samples of diabetic with a prevalence rate of 5.7% and 11.1% from nondiabetic patients.<sup>23</sup> In this study, *Candida* sp. represented 12% from total microbial isolates, 11.17%, 0.83% from diabetic and nondiabetic. A high prevalence rate of candiduria 84.2% was reported by Yismaw et al., 2013.<sup>26</sup>

In our study, diabetic illness high UTIs rate compare with nondiabetic. In a prior study, diabetes considerable hazard factors have been initiating as a stimulating factor for UTI in illness with diabetes.<sup>27</sup> In the present study, multidrug resistance bacteria (MDRB) were discovered. Meropenem, imipenem, trimethoprim/sulphamethoxazole, and norfloxacin most effective antibiotics against bacterial isolates. The antimicrobial resistance profile of the uropathogens, we observed that most *Escherichia coli* strains were resistant to amoxicillin, erythromycin, and vancomycin in both diabetic and nondiabetic patients. Raya et al., 2019 recorded the highest resistance bacterial isolates from UTIs to amoxicillin followed by ciprofloxacin and cotrimoxazole in diabetic and nondiabetic illnesses.<sup>28</sup> Also, Wang et al., 2013 reported that *Escherichia coli* resistance to second- and third-generation

cephalosporins were predominant in diabetic illness. Imipenem, nitrofurantoin, and amikacin were found to be highly effective antibiotics against *Escherichia coli*.<sup>29</sup>

*Klebsiella pneumonia* were found high resistance to amoxicillin, amoxicillin /clavulanic acid, ceftazidime, cephadrine, cefadroxil, cephalixin, ampicillin/sulbactam, erythromycin and vancomycin in both diabetic and nondiabetic patients. Thiraviam et al., 2014 isolated *Klebsiella* sp. from the urine culture of diabetic and nondiabetic patients which exhibit a variable resistance pattern to chloramphenicol, ampicillin, and streptomycin.<sup>30</sup> In this study, *Staphylococcus aureus* exhibit high sensitivity to amikacin, ciprofloxacin, gentamycin imipenem levofloxacin, meropenem, norfloxacin, ampicillin/sulbactam but 100% resistance to amoxicillin. Woldemariam et al., 2019 reported that *S. aureus* 100% sensitive to nitrofurantoin, however 100% resistance to ampicillin, trimethoprim/sulphamethoxazole, and penicillin.<sup>31</sup> Sertaç et al., 2018 isolated multidrug resistance *Staphylococcus* sp. from the ocular surface of patients with diabetes.<sup>32</sup>

## CONCLUSION

UTIs are less in the nondiabetic people as compared to their diabetes. Diabetes is a chronic disease a significant stimulates UTI. *E. coli* was the most frequent bacteria causing UTIs. The most effective antibiotics against bacteria species recovered from diabetic and nondiabetic illnesses were found meropenem, imipenem, trimethoprim/sulphamethoxazole, and norfloxacin.

## REFERENCES

1. International Diabetes Federation. IDF Diabetes Atlas, 5th edition Update, 2012. <http://www.idf.org/diabetesatlas/5e/Update>.
2. International Diabetes Federation. IDF Diabetes Atlas, 5th edition, 2011. <http://www.idf.org/diabetesatlas/5e/the-global-burden>.
3. World Health Organization (WHO). The top 10 causes of death. Fact sheet Nr. 310. Updated June 2011. <http://www.who.int/mediacentre/factsheets/fs310/en/ind ex.html>.
4. Vasudevan R. "Urinary tract infection: an overview of the infection and the associated risk factors," *Journal of Microbiology & Experimentation*. 2014; 1(2) 00008 .
5. Nerurkar, A.; Solanky, P. and Naik, S. S. "Bacterial pathogens in urinary tract infection and antibiotic susceptibility pattern," *Journal of Pharmaceutical and Biomedical Sciences*. 2012; 21.

6. Amit R. S., Dwij R. B. Jyotsna S., et al. Antimicrobial susceptibility pattern of *Escherichia coli* isolated from urinary tract infected patients attending Bir Hospital, Nepal. *J Sci Technol.* 2013; 14(1):177-84.
7. Durgesh D W, and Tuman PM. Prevalence and antibacterial susceptibility pattern of urinary tract infection causing human pathogenic bacteria. *Asian J Biomed Pharm Sci.* 2012; 2(15):1-3.
8. Hamza S., Lovely B., Ashraful H., et al. The pattern of organism causing urinary tract infection in diabetic and nondiabetic patients in Bangladesh. *Bangladesh J Med Microbiol.* 2010; 4(1):6-8.
9. Pragma S., et al. Antibiotic resistance among *Escherichia coli* isolates from stool samples of children aged 3 to 14 years from Ujjain India. *Bio-Med Central Inf Dis.* 2013; 13 .
10. Jharna M. N, Srinivas A. D, Buddhapriya S. et al. Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin-resistant *E.coli*. *Indian J Med Res.* 2012; 136:842-9 .
11. Collins H. C, Lyne M.P, Grange J. M, et al. *Microbiological Methods: 8th ed.* Arnold, 338 Euston Road, London NW1 3BH. 2004.
12. Bergey D. H., Krieg N. R, and Holt J. G. *Bergey's manual of systematic bacteriology.* 1<sup>st</sup> ed. 1984; Baltimore, MD: Williams & Wilkins.
13. Barnett A. J., Payne R. W, and Yarrow D. Laboratory methods for identifying yeasts, p. 2000; 23–38. In J. A. Barnett, R. W. Payne, and D. Yarrow (ed.), *Yeasts: characteristics and identification*, 3rd ed. Cambridge University Press, Cambridge, United Kingdom.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th ed. informational supplement. CLSI doc M100-S21. Wayne, Pa. 2015.
15. Clinical and Laboratory Standards Institute. Methods for Antifungal Disc Diffusion Susceptibility Testing: 3rd ed informational supplement. CLSI doc M44 replace M44-A2. 2018.
16. Livermore D. M, Struelens M., Amorim J, et al. Multicenter evaluation of Vitek 2 advanced expert system for an interpretive reading of antimicrobial resistance tests. *J. Antimicrob. Chemother* 49: 2002; 289-300.
17. Chaudhary BL, Charu C, Shukla S. Bacteriology of urinary tract infection and antibiotic susceptibility pattern among diabetic patients. *Int J Bioassays.* 2014; 3(08):3224–7.
18. Al-Qaseer A, Abdul-Wahab BH, Abbas OK. The bacteriological finding of urinary tract infection in diabetic patients. *Int. J. Adv. Res.* 2014; 2(10):274–9.
19. Muhammad I, Saeed A, Sohaib MK, et al. Urinary tract infection in diabetic patients; causative bacteria and antibiotic sensitivity. *J Med Sci.* 2014; 22(3):110–4.
20. Yismaw G, Asrat D, Woldeamanuel Y, et al. Prevalence of Candiduria in diabetic patients attending Gondar University hospital, Gondar, Ethiopia. *J. Kidney Dis.* 2013; 7(2):102–7.
21. Joshi N, Caputo GM, Weitekamp MR, et al. Infections in patients with diabetes mellitus. *N Engl J Med.* 1999; 341:1906–12.
22. Awwad K. Candiduria in diabetic patients in Arar northern area, *Saudi Arabia Life Sci J;* 2014; 11(1):336–70
23. Kumar R, Kumar R, Perswani P, et al. Clinical and Microbiological Profile of Urinary Tract Infections in Diabetic versus Non-Diabetic Individuals. 2019; *Cureus* 11(8): e5464. [DOI 10.7759/cureus.5464](https://doi.org/10.7759/cureus.5464)
24. Al-Asoufi, A., Ali K., Amjad A T., et al. Bacterial Quality of Urinary Tract Infections in Diabetic and Nondiabetics of the Population of Ma'an Province, *Jordan Pak. J. Biol. Sci.* 2017; 20 (4): 179-88,
25. Karmaker M., Santonu K. S., Munawar S. et al. Association of bacteria in diabetic and non-diabetic foot infection -An investigation in patients from Bangladesh. *Journal of Infection and Public Health.* 2016; 9, 267—77
26. Yismaw G, Asrat D, Woldeamanuel Y, et al. Prevalence of Candiduria in diabetic patients attending Gondar University hospital, Gondar, Ethiopia. *Iran. J. Kidney Dis.* 2013; 7(2):102–7
27. Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. *Indian J Endocrinol Metab.* 2012; 16(1): s27–36.
28. Raya S., Ankit B., Laxmi D., et al. In-Vitro Biofilm Formation and Antimicrobial Resistance of *Escherichia coli* in Diabetic and Nondiabetic Patients. *BioMed Research International.* 1474578, 8. 2019. <https://doi.org/10.1155/2019/1474578>
29. Wang M. C., Chin- Chung T., An-Bang W. et al. Bacterial characteristics and glycemic control in diabetic patients with *Escherichia coli* urinary tract infection. *Journal of Microbiology, Immunology, and Infection* 2013; 46, 24

30. Thiraviam M, Dereje Y, and Tamiru A. Antibiotic-resistant pattern of urinary tract infection causing *Escherichia coli* isolated from diabetic Mellitus and non-diabetic Mellitus patients with special reference to Rifampicin resistance. *Int J. Curr. Microbiol. App. Sci* 2014; 3(3): 668-74.
31. Woldemariam H. K., Dereje A. G., Kassu D.T. et al. Common uropathogens and their antibiotic susceptibility pattern among diabetic patients. *BMC Infectious Diseases*. 2019; 19: 9:43 <https://doi.org/10.1186/s12879-018-3669-5>
32. Sertaç A. K., Gizem A., Berna A. B, et al. Biofilm forming capacity and antibiotic susceptibility of *Staphylococcus* spp. with the *icaA/iPad/bap* genotype isolated from the ocular surface of patients with diabetes. *Malawi Medical Journal*. 2019; 30 (4); 243-9.